A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule
European Respiratory Journal · 2025-04 · 65 (4) · 2401461
DOI: 10.1183/13993003.01461-2024 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Respiratory Journal, online erschienen am 30.01.2025. Verfasst von Annemie Deiteren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Ghent, Belgium annemie.deiteren@sanofi.com. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Asthma, Single-Domain Antibodies. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Background
Monovalent biologics blocking thymic stromal lymphopoietin (TSLP) or interleukin (IL)-13 have been shown to elicit pharmacodynamic responses in asthma following a single dose. Therefore, dual blockade of these cytokines may result in an enhanced response compared to single targeting and has the potential to break efficacy ceilings in asthma. This study assessed the safety and tolerability of lunsekimig, a bispecific NANOBODY molecule that blocks TSLP and IL-13, and its effect on type 2 (T2) inflammatory biomarkers and lung function in asthma.
Methods
This was a phase 1b, single-dose (subcutaneous lunsekimig 400 mg or placebo), randomised (2:1), double-blind, proof-of-mechanism study in 36 participants with mild-to-moderate asthma and elevated exhaled nitric oxide fraction ( F ENO ; ≥25 ppb), a marker of airway inflammation. The primary end-point was safety and tolerability through day 71. The main pharmacodynamic secondary end-point was change from baseline in F ENO at day 29.
Results
Lunsekimig was well tolerated, with no serious treatment-emergent adverse events. F ENO was significantly reduced from day 8 through day 29 after a single dose, with change from baseline of −40.9 (90% CI −55.43– −26.39) ppb (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Sanofi, Ghent, Belgium annemie.deiteren@sanofi.com.
- Sanofi, Montpellier, France.
- Sanofi, Ghent, Belgium.
- Charité Research Organisation, Berlin, Germany.
- CRISPR Therapeutics, Boston, MA, USA.
- Sanofi, Bridgewater, NJ, USA.
Förderung
- Sanofi
Zitieren
APA
Deiteren, A., Krupka, E., Bontinck, L., Imberdis, K., Conickx, G., Bas, S., Patel, N., Staudinger, H. W., & Suratt, B. T. (2025). A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. European Respiratory Journal, 65(4), 2401461. https://doi.org/10.1183/13993003.01461-2024
Vancouver
Deiteren A, Krupka E, Bontinck L, Imberdis K, Conickx G, Bas S, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. European Respiratory Journal. 2025;65(4):2401461. doi:10.1183/13993003.01461-2024
BibTeX
@article{Deiteren2025,
author = {Deiteren, Annemie and Krupka, Emmanuel and Bontinck, Lieselot and Imberdis, Karine and Conickx, Griet and Bas, Selcuk and Patel, Naimish and Staudinger, Heribert W and Suratt, Benjamin T},
title = {A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule},
journal = {European Respiratory Journal},
year = {2025},
volume = {65},
number = {4},
pages = {2401461},
doi = {10.1183/13993003.01461-2024}
}
EUVIMED